Jefferies Financial Group’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-190,100
Closed -$262K – 1665
2024
Q4
$262K Buy
+190,100
New +$213K ﹤0.01% 1305

Other funds holding CHRS

Jefferies Financial Group's CHRS Position: Q2 2026 in Review

Jefferies Financial Group held its Coherus Oncology (CHRS) position steady in Q2 2026 at 252,000 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #1339.

Jefferies Financial Group first reported a position in CHRS in Q4 2022 and has held it in 14 quarters since. The position peaked at $893K in Q1 2023. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Jefferies Financial Group held 252,000 shares of Coherus Oncology worth $353K as of Q2 2026.
  • Jefferies Financial Group left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up ﹤0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #1339 holding.
  • Jefferies Financial Group first reported a position in Coherus Oncology in Q4 2022 and has held it in 14 quarters since.
  • Jefferies Financial Group's Coherus Oncology position peaked at $893K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.